Molecular detection of isoniazid and rifampin-resistant Mycobacterium tuberculosis strains from southwest of Iran
DOI:
https://doi.org/10.15584/ejcem.2026.2.15Keywords:
drug resistance, isoniazid, mutation, Mycobacterium tuberculosis, rifampinAbstract
Introduction and aim. The study of molecular mechanisms of resistance to first-line antibiotics for the treatment of tuberculosis is of great importance. Investigating these mechanisms provides valuable information to treatment policy makers. Therefore, this study aimed to identify mutations associated with resistance to rifampin (RIF) and isoniazid (INH) among drug-resistant Mycobacterium tuberculosis (MTB) isolates from a TB reference center in southwest Iran.
Material and methods. In this cross-sectional study (September 2014-February 2018), a total of 772 MTB isolates were confirmed by culture on Löwenstein-Jensen (LJ) medium and standard biochemical tests. Drug susceptibility testing of RIF and INH was determined by the proportion method on LJ medium. Mutations conferring resistance to INH and RIF were determined by polymerase chain reaction analysis and sequencing.
Results. In this study, 772 (22.68%) MTB strains were isolated from 3,404 TB-suspected patients, of whom 26.6% were women and 73.8% male. Of the 772 clinical strains, 8 (1.03%) were MDR (resistant to INH and RIF), 15 (1.94%) were resistant to RIF and 4 (0.5%) were resistant to INH. Of the 12 identified isolates identified (including both 4 isolates resistant to INH and 8 isolates resistant to MDR), 2 (16.6%) had a mutation at codon 315 of katG, 1 (8.33%) had a mutation at (-15) of inhA, and 9 (75%) did not show a detectable mutation. Regarding rifampin, the frequency of mutations in the rpoB gene was the following: codons 531 (n=7, 30.4%), 533 (n=5, 21.7%), 526 (n = 2, 8.69%) and 511 (n=1, 4.3%). Furthermore, no mutations were detected in 8 (34.7%) isolates.
Conclusion. The most prevalent mutation in INH resistant isolates was at codon 315 of katG. In RIF-resiatant isolates, the most prevalent mutation was at codon 531 of the rpoB gene. In a considerable number of isolates, no mutations in katG, inhA, and rpoB were found compared with deposited sequences available from NCBI GenBank.
Downloads
References
Soliman NS. Prevalence of multidrug-resistant tuberculosis using phenotypic drug susceptibility testing and genexpert mtb/rif with characterization of non-tuberculous mycobacteria using MALDI-TOF. Egypt J Med Microbiol. 2021;30(3):143-151. doi:10.51429/EJMM3031
Gholizadeh P, Pourlak T, Asgharzadeh M, et al. Gene mutations related to rifampin resistance of tuberculosis in northwest of Iran. Gene Rep. 2020;19:100672. doi:10.1016/j.genrep.2020.100672
Global Tuberculosis Report. World Health organization 2024. Geneva , Switzerland: World Health Organization; 2024. Accessed January 22, 2026. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.
Motavaf B, Keshavarz N, Ghorbanian F, et al. Detection of genomic mutations in katG and rpoB genes among multidrug-resistant Mycobacterium tuberculosis isolates from Tehran, Iran. New Microbes New Infect. 2021;41:100879. doi:10.1016/j.nmni.2021.100879
Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin-resistant Mycobacterium tuberculosis in Ethiopia: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207-218. doi:10.1016/j.jgar.2021.06.009
Hsu LY, Lai LY, Hsieh PF, et al. Two novel katG mutations conferring isoniazid resistance in Mycobacterium tuberculosis. Front Microbiol. 2020;11:1644. doi:10.3389/fmicb.2020.01644
Khan AS, Phelan JE, Khan MT, et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. Sci Rep. 2021;11(1):1-10. doi:10.1038/s41598-021-93501-4
Thwe EP, Namwat W, Pinlaor P, Rueangsak K, Sangka A. Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from north east of Thailand. World J Microbiol Biotechnol. 2021;37:1-9. doi:10.21203/rs.3.rs-648869/v1
Zenteno-Cuevas R, Cuevas-Córdoba B, Parissi-Crivelli A. rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from Southeast Mexico. Enferm Infecc Microbiol Clin. 2019;37(5):307-313. doi:10.1016/j.eimc.2018.09.002
Hamed Z, Mohajeri P, Farahani A, et al. The frequency of point mutations associated with resistance to isoniazid and rifampin among clinical isolates of multidrug-resistant Mycobacterium tuberculosis in the west of Iran. Gene Rep. 2021;22:100981. doi:10.1016/j.genrep.2020.100981
World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva, Switzerland: World Health Organization; 2018. (WHO/CDS/TB/2018.24)
Silva MSN, Senna SG, Ribeiro MO, et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol. 2003;41(9):4471-4474. doi:10.1128/jcm.41.9.4471-4474.2003
Pozzi G, Meloni M, Iona E, et al. rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin Microbiol. 1999;37(4):1197-1199. doi:10.1128/jcm.37.4.1197-1199.1999
Chen X, Kong f, Wang Q, Li C, Zhang J, Gilbert GL. Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis. J Clin Microbiol. 2011;49(10):3450-3457. doi:10.1128/jcm.01068-11
Yazdansetad S, Alkhudhairy MK, Najafpour R, et al. Preliminary survey of extended-spectrum β-lactamases (ESBLs) in nosocomial uropathogen Klebsiella pneumoniae in north-central Iran. Heliyon. 2019;5(9):e02349. doi:10.1016/j.heliyon.2019.e02349
Afrough P, Pourmand M R, Sarajian AA, et al. Molecular investigation of Staphylococcus aureus, coa and spa genes in Ahvaz hospitals, staff nose compared with patients clinical samples. Jundishapur J Microbiol. 2013;6(4):5377. doi:10.5812/jjm.5377
Sheikh AF, Moosavian M, Abdi M, et al. Prevalence and antimicrobial resistance of Shigella species isolated from diarrheal patients in Ahvaz, southwest Iran. Infect Drug Resist. 2019;12:249-253. doi:10.2147/IDR.S187861
Bainomugisa A, Lavu E, Pandey S, et al. Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea. BMC Infect Dis. 2022;22(1):437. doi:10.1186/s12879-022-07414-2
Li D, Song Y, Zhang CL, Li X, Xia X, Zhang AM. Screening mutations in drug-resistant Mycobacterium tuberculosis strains in Yunnan, China. J Infect Public Health. 2017;10(5):630-636. https://doi.org/10.1016/j.jiph.2017.04.008
Khademi F, Sahebkar A. An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020). Iran J Basic Med Sci. 2021;24(4):428. doi:10.22038/IJBMS.2021.48628.11161
Charan AS, Gupta N, Dixit R, et al. Pattern of inhA and katG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates. Lung India. 2020;37(3):227-231. doi:10.4103/lungindia.lungindia_204_19
Villegas L, Otero L, Sterling TR, et al. Prevalence, risk factors, and treatment outcomes of isoniazid-and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru. PloS One. 2016;11(4):e0152933. doi:10.1371/journal.pone.0152933
Solo ES, Nakajima C, Kaile T, et al. Mutations in rpoB and katG genes and the inhA operon in multidrug-resistant Mycobacterium tuberculosis isolates from Zambia. J Glob Antimicrob Resist. 2020;22:302-307. doi:10.1016/j.jgar.2020.02.026
Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PloS One. 2015;10(3):e0119628. doi:10.1371/journal.pone.0119628
Le Hang NT, Hijikata M, Maeda S, et al. Whole genome sequencing, analyses of drug resistance-conferring mutations, and correlation with transmission of Mycobacterium tuberculosis carrying katG-S315T in Hanoi, Vietnam. Sci Rep. 2019;9(1):1-14. doi:10.1038/s41598-019-51812-7
Munir A, Kumar N, Ramalingam SB, et al. Identification and characterization of genetic determinants of isoniazid and rifampicin resistance in Mycobacterium tuberculosis in southern India. Sci Rep. 2019;9(1):1-13. doi:10.1038/s41598-019-46756-x
Ruesen C, Riza AL, Florescu A, et al. Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania. Sci Rep. 2018;8(1):1-8. doi:10.1038/s41598-018-27962-5
Abanda NN, Djieugoué JY, Lim E, et al. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon: A cross-sectional study. BMC Infect Dis. 2017;17(1):1-10. doi:10.1186/s12879-017-2489-3
Dantes R, Metcalfe J, Kim E, et al. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PloS One. 2012;7(5):e37956. doi:10.1371/journal.pone.0037956
Anwaierjiang A, Wang Q, Liu H, et al. Prevalence and molecular characteristics based on whole genome sequencing of Mycobacterium tuberculosis resistant to four anti-tuberculosis drugs from Southern Xinjiang, China. Infect Drug Resist. 2021;14:3379. doi:10.2147/IDR.S320024
Miotto P, Saleri N, Dembelé M, et al. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis. 2009;9(1):1-8. doi:10.1186/1471-2334-9-142
Diandé S, Ogbomon E, Gueye A. Occurrence of mutations associated with rifampicin and isoniazid resistant in Mycobacterium tuberculosis isolates from patients in Burkina Faso. Int J Mol Biol. 2019;4(3):106-111. doi:10.15406/ijmboa.2019.04.00105
Pinhata JMW, Brandao AP, de Freitas Mendes F, da Silva Rabello MC, Ferrazoli L, de Oliveira RS. Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting. Eur J Clin Microbiol Infect Dis. 2021;40:2551-2561. doi:10.1007/s10096-021-04316-0
Ayalew S, Wegayehu T, Taye H, et al. Drug resistance conferring mutation and genetic diversity of Mycobacterium tuberculosis isolates in tuberculosis lymphadenitis patients; Ethiopia. Infect Drug Resist. 2021;14:575. doi:10.2147/IDR.S298683
Siddiqui S, Brooks MB, Malik AA, et al. Evaluation of GenoType MTBDR plus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan. PloS One. 2019;14(8):e0221485. doi:10.1371/journal.pone.0221485.t001
Zurita J, Espinel N, Barba P, et al. Genetic diversity and drug resistance of Mycobacterium tuberculosis in Ecuador. Int J Tuberc Lung Dis. 2019;23(2):166-173. doi:10.5588/ijtld.18.0095
Prasad PG, Jasmine MS, Deepthi K, Allam US. Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India. Braz J Infect Dis. 2019;23(2):281-290. doi:10.1016/j.bjid.2019.07.002
Singhal R, Myneedu V, Arora J, et al. Early detection of multi-drug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoType MTBDRplus assay. Indian J Med Microbiol. 2015;33:S46-S52. doi:10.4103/0255-0857.150879
Haratiasl AA, Hamzelou G, Amini S, et al. Molecular identification of mutations conferring resistance to rifampin, isoniazid and pyrazinamide among Mycobacterium tuberculosis isolates from Iran. J Chemother. 2020;32(2):75-82. doi:10.1080/1120009X.2020.1716479
Farra A, Koula K, Jolly BL, et al. Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic. PLOS Glob Public Health. 2023;3(5):e0001847. doi:10.1371/journal.pgph.0001847
Wang H, Ye C, Jiang H, Song R. Application of next-generation sequencing in the detection of antimicrobial resistance. Clin Chim Acta. 2025;578:120520. doi:10.1016/j.cca.2025.120520
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
